Education & Events
by Cochlear Guest Author

Normal hearing is 20/20: Audiology Awareness Month

October 7, 2020
Share

New public health campaign seeks to establish a simple health metric to define normal hearing to better monitor hearing loss, refer for treatment

LONE TREE, Colo., Oct. 7, 2020 /PRNewswire/ — Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, launches the Hearing 20/20 campaign, a new public health initiative to adopt 20/20 as a common metric for normal hearing, during October’s Audiology Awareness Month. Supported by 10 hearing health nonprofit and industry partners, establishing a simple, common metric, defined as 20 decibels in each ear, can help simplify the ongoing conversation and actions related to monitoring hearing health and treating hearing loss, especially among adults 55 years of age and older.

According to the Centers for Disease Control and Prevention (CDC), hearing loss is the third most common chronic physical condition impacting adults in the United States, and hearing loss is more prevalent than diabetes or cancer.1 However, hearing is not a mandatory part of an individual’s annual physical screening and generally is deprioritized amongst consumers and primary care providers2, even though studies continue to prove untreated hearing loss has a sizable negative impact on an individual’s overall health3.

Research conducted by Cochlear found 93 percent of consumers know what normal vision is, but only 9 percent can define normal hearing.2 Seventy-seven percent of consumers turn to their primary care providers for hearing loss information, but 75 percent of consumers do not complete annual hearing exams.2 Additionally, 47 percent of consumers prioritize their pet’s annual exam over getting their hearing checked annually.2

“Hearing health should be prioritized as a significant part of a person’s overall health, especially as we age,” said Joanna T. Smith, MS CCC-SLP, LSLS Cert., AVT, Founder, CEO and Executive Director, Hearts for Hearing. “Like vision, normal hearing is 20/20. Everyone should get to know their hearing number by requesting a hearing test at their next doctor’s visit and should continue checking their hearing health annually thereafter. We all know hearing loss can negatively impact a person’s quality of life; however, hearing loss is treatable and not something we just have to live with.”

For healthcare providers treating patients during an annual physical, a simple way to screen for hearing loss is wash your hands during the appointment. With the water running and back to the patient, ask a few questions. If they do not respond or the answers do not match what was asked, it is appropriate to start a conversation about hearing loss and discuss referring for a hearing test.4 For consumers and their loved ones, they should request a hearing test at their next annual physical so they can learn their hearing number.

Proper audiometric testing is needed to determine a person’s hearing number. The testing, typically done by an audiologist, can provide a summary of a person’s hearing status via an audiogram. During the testing, hearing thresholds are measured in decibels (dB) for each ear using pure tones across a range of frequencies (Hz). Pure-tone average (PTA) refers to the average of hearing thresholds at a set of specified frequencies and can indicate a hearing level for each ear. As such, a hearing level from 0 to 20 dB PTA in each ear is considered normal. Numbers exceeding 20 dB could benefit from amplification, such as hearing aids, while levels above 60 dB suggest a referral for a cochlear implant evaluation.5 Cochlear is proposing hearing health professionals use the PTA as a simple, easy to remember metric for consumers to track their hearing levels.

“We understand a PTA measurement is a very simplified metric amongst a complex battery of testing that hearing health professionals perform. However, if we want to help more people hear, we need to communicate simple metrics and help consumers and referring professionals adopt them much like other health metrics. Then we can help those who need treatment, like hearing aids or cochlear implants that are widely underutilized, hear better sooner and help increase quality of life earlier as well,” said Patricia Trautwein, AuD, Vice President, Product Management & Marketing, Cochlear Americas.

According to the National Institutes of Health (NIH), one in every three people 65 years of age and one in every two 75 years of age and over has hearing loss.6 The World Health Organization (WHO) estimates there are 72 million people who could potentially benefit from the use of a hearing device, such as a hearing aid or cochlear implant.7 However, on average, people with hearing loss wait six years to get their hearing loss treated.8 By 2030, all Baby Boomers will be 65 years and older and this generation will live longer than any generation in history.9 Prioritizing hearing health is necessary now to help aging adults live active, healthy and independent lives as long as possible.

This is the first phase of a multi-year initiative to educate the public about the importance of hearing health. To learn your hearing number, find a local audiologist near you from the directories linked on the Hearing2020.com website. Industry and nonprofit partners supporting the campaign include American Academy of Audiology, Academy of Doctors of Audiology, Hearing Loss Association of America, A.G. Bell, Hearing Health Foundation, Hearing First, Hearing Industries Association, American Cochlear Implant Alliance, Songs for Sound and Ear Community.

About Cochlear Limited (ASX: COH)
Cochlear is the global leader in implantable hearing solutions. The company has a global workforce of more than 4,000 people and invests more than AUD$180 million each year in research and development. Products include cochlear implants, bone conduction implants and acoustic implants, which healthcare professionals use to treat a range of moderate to profound types of hearing loss.

Since 1981, Cochlear has provided more than 600,000 implantable devices, helping people of all ages, in more than 180 countries, to hear. www.cochlear.com/us

References

  1. Blackwell DL, Lucas JW, Clarke TC. Summary health statistics for US adults: National Health Interview Survey, 2012. Vital health statistics, series 10, no. 260. Atlanta, GA: National Center for Health Statistics, CDC; 2014. https://www.cdc.gov/nchs/data/series/sr_10/sr10_260.pdf
  2. May 29, 2019 Cochlear 20/20 hearing study. Survey of 1,250 conducted by Penn, Schoen, Berland, March 13, 2019. Data on file.
  3. Brody, J. E. (2018, December 31). Hearing Loss Threatens Mind, Life and Limb. Available from: https://www.nytimes.com/2018/12/31/well/live/hearing-loss-threatens-mind-life-and-limb.html.
  4. Strait, J.E. (2020, August 27). Cochlear implants should be recommended for adults more often. Available from: https://medicine.wustl.edu/news/cochlear-implants-should-be-recommended-much-more-often-for-adults-with-hearing-loss/#:~:text=An%20international%20group%20of%20hearing,than%20is%20the%20current%20practice.
  5. Zwolan TA, Schvartz-Leyzac KC, Pleasant T. Development of a 60/60 guideline for referring adults for a traditional Cochlear implant candidacy evaluation. Otol Neurotol 2020;41:895-900.
  6. Hearing Loss and Older Adults [Internet]. National Institute on Deafness and Other Communication Disorders; c2018 [cited 11 Sept 2020]. Available from: https://www.nidcd.nih.gov/health/hearing-loss-older-adults.
  7. Deafness and hearing loss fact sheet [Internet]. World Health Organization; c2020 [cited 11 Sept 2020]. Available from: https://www.who.int/mediacentre/factsheets/fs300/en/.
  8. Hearing Industries Association. MT10 MarkeTrak 10 Base Report. Washington, DC: Marketing Research, Inc; March 27, 2019.
  9. America Counts Staff (2019, December 10). 2020 Census Will Help Policymakers Prepare for the Incoming Wave of Aging Boomers. Available from: https://www.census.gov/library/stories/2019/12/by-2030-all-baby-boomers-will-be-age-65-or-older.html.

SOURCE Cochlear Limited

Please seek advice from your health professional about treatments for hearing loss. Outcomes may vary, and your health professional will advise you about the factors which could affect your outcome. Always read the instructions for use. Not all products are available in all countries. Please contact your local Cochlear representative for product information.

© Cochlear Limited 2020. All rights reserved.

Author

Cochlear Guest Author

In an effort to keep our content fresh and reflective of a diverse industry, Cochlear Americas features a mix of employees and professional partners to contribute to Cochlear ProNews as Guest Authors.

View all posts

Related Posts
ADA 2021

ADA Conference – AuDacity 2021 Audiology Unleashed

October 14, 2021

ADA Conference – AuDacity 2021 Audiology Unleashed

We’re looking forward to participating in the AuDacity 2021 conference on October 25th -27th, presented by Academy of Doctors of Audiology (ADA)! Come visit us in the Exhibitor Hall to learn about new product information, referral criteria and services to help you and your patients.  In addition, join us for an exciting presentation, on Monday, October 25, 2021 @ 3:00PM – 4:25PM.

Presented by Ginger Grant, Au.D., Professional Education Manager and Catherine Richardson, M.A., Director Market Expansion and Integration

The Keys to Successful Integration of Implantable Hearing Solutions in a Private Practice

Adding any new service to an audiologist’s private practice offering requires extensive consideration of business growth and development requirements and opportunities while always focusing on obtaining the best possible patient outcomes. It is now well established that audiologists in a private practice setting can successfully integrate implantable hearing solutions, allowing providers to both keep existing and attract new patients, while developing partnerships in the medical community and tapping into an alternate revenue source for the practice. The purpose of this session is to review various considerations necessary to elevate this opportunity to the highest level for the practice owners and patients alike. To learn more about the session, please visit AuDacity 2021 – conference agenda.

Clinical Application and Resources for Cochlear™ Bone Conduction Solutions

June 16, 2023

Bone conduction solutions are a well-established treatment option for patients with conductive hearing loss, mixed conductive-sensorineural hearing loss, and single-sided deafness. Options such as the Cochlear™ Osia® System*, Baha® Start or Baha® System** are predictable and cost-effective solutions that provide excellent hearing outcomes.1    With the introduction of Cochlear’s Candidacy, Evaluation and Fitting Protocol for Bone Conduction Solutions, clinics looking to begin or expand treating patients with a bone conduction solution, like the Osia System, have a roadmap to help them establish a consistent and evidence-based treatment practice.2

The Osia System revolutionized clinical treatment for patients by applying digital piezoelectric stimulation to become the world’s first active osseointegrated steady-state implant (OSI). The Osia System first received FDA approval in December 2019, and Cochlear recently celebrated the 10,000th Osia System recipient!

Incorporating bone conduction solutions into clinical treatment protocols

Justyn Pisa, AuD, and the team at the Surgical Hearing Implant Program in Manitoba provided insights into integrating bone conduction solutions into a medical portfolio of treatment options.

“Bone conduction options are part of our treatment course for conductive or mixed hearing losses (provided bone conduction thresholds are within acceptable limits). 

We do prefer to see bone conduction thresholds of 45 dB or better in mixed losses, but not every potential candidate presents with ideal circumstances, so we try to match them with the best potential option on a case-by-case basis. 

In general, we have our patients trial conventional amplification prior to receiving a bone conduction solution.  However, in cases where hearing aids are not an option, we will look at a bone conduction solution first, either on a headband or implant.

We have fairly good communication between surgeons and audiologists on new referrals and potential candidates prior to surgery.  In many cases, new patients are referred for assessment by our surgeon Dr. Garber or other public health audiologists in Canada who encounter patients with long-standing/permanent conductive hearing loss.

I try to ensure everyone is up to date on new candidates and will assist the scheduling clerk on medical assessment appointments once they’ve been cleared by audiology. 

We have begun quarterly team meetings to review program needs, new technology, and our wait list for surgery.  We generally use this time to discuss specific patients and potential outcomes with different implant options.” 

Clinics looking to start offering Osia or Baha Systems into their treatment protocols, just like Justyn Pisa, AuD, and the Surgical Hearing Implant Program in Manitoba have done, have several clinical resources available to help them get started. These include Cochlear’s Candidacy, Evaluation, and Fitting Protocol for Bone Conduction Solutions, as well as  including Otologic Management Services Insurance Support, our expert insurance and reimbursement team.

References

  1. Evans AK, Kazahaya K. Canal atresia: “Surgery or implantable hearing devices? The experts question is revisited” Journal of Pediatric Otorhinolaryngology 2007; 71, 367-374
  2. OSI140 ISS1 FEB23 Bone Conduction Protocol Whitepaper
  3. de Wolf MJ, Hendrix S, Cremers CW, Snik AF. Better performance with bone‐anchored hearing aid than acoustic devices in patients with severe air‐bone gap. Laryngoscope. 2011;121:613-616.

*In the United States, the Osia 2 System is cleared for children ages twelve and older. In Canada, the Osia 2 System is approved for children ages five and older

**In the United States and Canada, the placement of a bone-anchored implant is contraindicated in children below the age of five.

***In the United States and Canada, the Nucleus System for single-sided deafness is approved for children ages five and older.

Cochlear logo - white

©Cochlear Limited 2024. All rights reserved. ACE, Advance Off-Stylet, AOS, Ardium, AutoNRT, Autosensitivity, Baha, Baha SoftWear, BCDrive, Beam, Bring Back the Beat, Button, Carina, Cochlear, 科利耳, コクレア, 코클리어, Cochlear SoftWear, Contour, コントゥア, Contour Advance, Custom Sound, DermaLock, Freedom, Hear now. And always, Hugfit, Human Design, Hybrid, Invisible Hearing, Kanso, LowPro, MET, MP3000, myCochlear, mySmartSound, NRT, Nucleus, Osia, Outcome Focused Fitting, Off-Stylet, Piezo Power, Profile, Slimline, SmartSound, Softip, SoundArc, True Wireless, the elliptical logo, Vistafix, Whisper, WindShield and Xidium are either trademarks or registered trademarks of the Cochlear group of companies. The names of actual companies and products mentioned herein may be the trademarks of their respective owners.

 

This material is intended for health professionals. If you are a consumer, please seek advice from your health professional about treatments for hearing loss. Outcomes may vary, and your health professional will advise you about the factors which could affect your outcome. Always read the instructions for use. Not all products are available in all countries. Please contact your local Cochlear representative for product information.

 

Cochlear ProNews is monitored Monday through Friday, excluding some holidays. Questions and inquiries submitted over the weekends or holidays may see a delay in response. For immediate assistance please contact us directly. You are solely responsible for your interactions with other members of our Websites. Cochlear reserves the right, but has no obligation, to monitor disputes or communications between you and other members of our Websites. For a full list of Cochlear’s terms of use, click here.